High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

  title={High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.},
  author={Claire Dearden and Estella Matutes and Bruno Cazin and Geir Erland Tj{\o}nnfjord and Ant{\'o}nio Parreira and Benet Nomdedeu and Pietro Leoni and Fiona J. Clark and Deepti H Radia and Saad M. B. Rassam and Tony Roques and Nicolas Ketterer and Vasantha Brito‐Babapulle and M. J. S. Dyer and Daniel Catovsky},
  volume={98 6},
T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-resistant malignancy with a median survival of 7.5 months. Preliminary results indicated a high remission induction rate with the human CD52 antibody, CAMPATH-1H. This study reports results in 39 patients with T-PLL treated with CAMPATH-1H between March 1993 and May 2000. All but 2 patients had received prior therapy with a variety of agents, including 30 with pentostatin; none achieved complete remission (CR). CAMPATH-1H (30 mg) was… 

Figures and Tables from this paper

T-cell prolymphocytic leukemia

T-cell prolymphocytic leukemia is a rare aggressive post-thymic malignancy with poor response to conventional treatment and short survival, and strategies using both autologous and allogeneic stem cell transplantation are currently being explored.

How I treat prolymphocytic leukemia.

The role of allogeneic transplant with nonmyeloablative conditioning needs to be explored further in both T- and B-cell PLL to broaden the patient eligibility for what may be a curative treatment.

Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.

Cytomegalovirus viremia may be a significant infectious complication during Campath-1H therapy and should be investigated further in future studies.

Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center

An open-label clinical trial and the clinical use of alemtuzumab in 19 heavily pretreated patients with advanced erythrodermic cutaneous T-cell lymphomas (CTCL) with acceptable toxicities are presented.

Peripheral T-cell lymphomas: diagnosis and management.

T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches

Newer approaches in the treatment of T-PLL are developing based on recognizing the cytogenetic phenotype of each patient and targeting the identified defective genes that are usually involved in the cell cycle regulation such as protooncogenes, tumor suppressors, and deoxyribonucleic acid (DNA) repair genes that could potentially redirect the management in the near future.

Primary refractory T‐cell prolymphocytic leukaemia treated with daily administration of Alemtuzumab plus high‐dose methylprednisolone

An entirely non-chemotherapy approach, using escalated Alemtuzumab dosing (daily administration) combined with high-dose methylprednisolone (HDMP) and ascitic drainage, resulted in rapid disease control and complete remission in a patient with T-PLL.

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)

  • P. JainE. Aoki T. Kadia
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
Outcomes in T-PLL remain poor and complex karyotype and aberrations in chromosome 14 were seen in 65% and 52% patients, respectively, and stem cell transplantation was not associated with longer PFS and OS.

T-cell prolymphocytic leukemia

There is no standard therapy for the relapse, although, based on genome studies, many drugs may be potentially effective, including histone deacetylase inhibitors and BCL2 inhibitors.



Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.

  • R. PawsonM. Dyer D. Catovsky
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
CAMPATH-1H alone is not sufficient for long-term remissions, and the role of autologous stem-cell transplantation needs further investigation, but it represents a significant improvement over other types of therapy.

The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.

It is concluded that DCF is effective as a single agent in T-PLL, Sézary syndrome, and LGL leukemia, but has low activity in other T-cell disorders.

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

  • A. OsterborgM. Dyer H. Mellstedt
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
CAMPATH-1H had significant activity in patients with advanced and chemotherapy-resistant CLL, and the most pronounced effects were noted in blood, bone marrow, and spleen.

Indolent course as a relatively frequent presentation in T‐prolymphocytic leukaemia

T‐PLL may start as an indolent disease similar to that reported in ataxia telangectasia, and in this rare genetic disorder, some patients develop stable T‐cell clones which progress toward T‐P LL‐like leukaemia.

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

This study demonstrates that this nonmyeloablative preparative regimen is associated with durable engraftment, minimal toxicity, and low incidence of GVHD.


Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation

A 47-year-old male with refractory T-PLL who was treated with high-dose chemoradiotherapy and allogeneic bone marrow transplantation from an HLA-matched sibling achieves complete remission and remains in remission 3 years after the transplant.

In vivo‘Purging’ of residual disease in CLL with Campath‐1H

Treatment with Campath‐1H may be of value in eradicating residual disease in CLL and may facilitate high‐dose therapy in young patients.

Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia.

The clinical course was progressive with a median survival of 7.5 months and the response rate increased to 58% in patients with a CD4+ CD8- phenotype, and a subgroup of patients may benefit from deoxycoformycin.